Synthelis provides a solution to a well known challenge in terms of biotechnological production – namely the synthesized production of membrane proteins. Around 30% of the human genome is coded for protein membranes. This family of proteins is involved in key biological processes such as cellular signaling, energy transduction or metabolic transportation. Anomalies affecting their structure or function can be directly or indirectly linked to a large number of pathologies. Consequently these molecules are the target for a large number of medicines currently planned for development.